Human safety, tolerability, and pharmacokinetics of a novel broad-spectrum oral antiviral compound, molnupiravir, with activity against SARS-CoV-2
WP Painter, W Holman, JA Bush, F Almazedi, H Malik… - medrxiv, 2020 - medrxiv.org
Abstract Molnupiravir, EIDD-2801/MK-4482, the prodrug of the ribonucleoside analog ß-d-
N4-hydroxycytidine (NHC), has activity against a number of RNA viruses including severe …
N4-hydroxycytidine (NHC), has activity against a number of RNA viruses including severe …
Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2
WP Painter, W Holman, JA Bush… - Antimicrobial agents …, 2021 - Am Soc Microbiol
ABSTRACT Molnupiravir (EIDD-2801/MK-4482), the prodrug of the active antiviral
ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931), has activity against a …
ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931), has activity against a …
Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2
W Holman, W Holman, S McIntosh, W Painter… - Trials, 2021 - Springer
A recently published article described the safety, tolerability, and pharmacokinetic profile of
molnupiravir (Painter et al. 2021), a novel antiviral agent with potent activity against severe …
molnupiravir (Painter et al. 2021), a novel antiviral agent with potent activity against severe …
A phase I, randomized, placebo‐controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID‐19
K Nakamura, K Fujimoto, C Hasegawa… - Clinical and …, 2022 - Wiley Online Library
Abstract Molnupiravir (MK‐4482) is an oral prodrug of the antiviral ribonucleoside analog, N‐
hydroxycytidine (NHC), which has activity against RNA viruses, including severe acute …
hydroxycytidine (NHC), which has activity against RNA viruses, including severe acute …
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
SH Khoo, R Fitzgerald, T Fletcher… - Journal of …, 2021 - academic.oup.com
Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …
Molnupiravir—a novel oral anti-SARS-CoV-2 agent
Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral …
rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral …
Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19
HB Rasmussen, PR Hansen - Viruses, 2023 - mdpi.com
Molnupiravir, a prodrug known for its broad antiviral activity, has demonstrated efficacy in
animal models of COVID-19, prompting clinical trials, in which initial results indicated a …
animal models of COVID-19, prompting clinical trials, in which initial results indicated a …
Phase 2/3 trial of molnupiravir for treatment of Covid-19 in nonhospitalized adults
Y Caraco, GE Crofoot, PA Moncada… - NEJM …, 2022 - evidence.nejm.org
Background Safe and effective oral treatments are needed to improve clinical outcomes for
nonhospitalized patients with Covid-19. Molnupiravir is an orally administered, small …
nonhospitalized patients with Covid-19. Molnupiravir is an orally administered, small …
Molnupiravir, an oral antiviral treatment for COVID-19
Background Easily distributed oral antivirals are urgently needed to treat coronavirus
disease-2019 (COVID-19), prevent progression to severe illness, and block transmission of …
disease-2019 (COVID-19), prevent progression to severe illness, and block transmission of …
[HTML][HTML] The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review
Background Throughout the time of the global pandemic of SARS-CoV-2 virus, there has
been a compelling necessity for the development of effective antiviral agents and …
been a compelling necessity for the development of effective antiviral agents and …